Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ADHANSIA XR

METHYLPHENIDATE HYDROCHLORIDE

Standard Dose
35MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ADHANSIA XR is listed in Drugs@FDA under application 212038 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient METHYLPHENIDATE HYDROCHLORIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 35MG Sponsor PURDUE PHARMA LP Submission history Latest submission status date: 2021-06-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview ADHANSIA XR is listed in Drugs@FDA under application 212038 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHYLPHENIDATE HYDROCHLORIDE Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 35MG Sponsor PURDUE PHARMA LP Submission history Latest submission status date: 2021-06-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ADHANSIA XR (METHYLPHENIDATE HYDROCHLORIDE) | Drug Monograph | MedicHelpline